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Background: Sunitinib interacts with radiation therapy, leading to synergism of the toxicities of these treatments.
Radiation recall pneumonitis is a rare but serious complication of targeted therapy with tyrosine kinase inhibitors.
Case presentation: The case of a patient with metastatic renal cell cancer (RCC) who developed recall
pneumonitis on the first cycle of systemic sunitinib treatment is reported here. A 65-year-old man with RCC and
bone metastasis underwent radiation therapy on his thoracic vertebrae (Th5-8) with a total dose of 24 Gy. Sunitinib
(37.5 mg) was started 14 days after completing the radiation therapy. On the 14th day of sunitinib treatment, the
patient developed progressive fever with worsening of dyspnea and general weakness. Treatment with pulse
administration of prednisolone 1,000 mg for 3 days was initiated. Thereafter, the symptoms and the radiological
findings regarding the interstitial filtration gradually improved over 7 days.
Conclusion: To our knowledge, this is the first report of early onset recall pneumonitis during sunitinib therapy. At
present, how sunitinib interacts with radiation therapy remains unclear. The possibility that tyrosine kinase inhibitor
therapy, including with sunitinib, after radiation therapy may lead to adverse effects should be kept in mind.
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Renal cell cancer (RCC) is the most lethal of the uro-
logical malignancies, and its incidence is currently in-
creasing [1]. Recently, several new targeted agents were
introduced in the clinical treatment of metastatic RCC.
One of these agents, sunitinib, is an orally administered
tyrosine kinase inhibitor with multiple targets, including
vascular endothelial growth factor receptor (VEGFR)-1,
VEGFR-2, VEGFR-3, platelet-derived growth factor re-
ceptor (PDGFR)-α, and PDGFR-β. Sunitinib is one of
the most widely prescribed drugs for the treatment of
metastatic RCC [2]. The adverse effects of sunitinib in-
clude fatigue, bone marrow suppression, hand-foot syn-
drome, stomatitis, hypertension, and hypothyroidism [3].
Interstitial lung disease is a rare but serious complication
of targeted therapy with tyrosine kinase inhibitors, in-
cluding sunitinib. The case of a patient with metastatic* Correspondence: takeshi.yuasa@jfcr.or.jp
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reproduction in any medium, provided the orRCC who developed recall pneumonitis on the 14th
day of systemic sunitinib treatment is described here.
There is currently only one report of recall pneumonitis
during sunitinib therapy in the literature [4]. The time of
onset in that case was quite different from that in the
present case.
Case presentation
A 65-year-old man with clear cell RCC and lung
metastasis was initially treated by right nephrectomy on
November, 2011 (pT2b, N0, M1). On January, 2012, du-
ring the follow-up period, bilateral lower limb paralysis
occurred due to spinal compression from RCC bone me-
tastasis (Figure 1A). He underwent radiation therapy on
his thoracic vertebrae (Th5-8) with a total dose of 24 Gy
that was divided into six fractions (Figure 1B and C).
Sunitinib (37.5 mg) was started 14 days after completing
the radiation therapy. On the 14th day of sunitinib treat-
ment, the patient complained of high fever and the chest
CT disclosed bilateral lung consolidation (Figure 2A). At
this time, blood culture examinations did not reveal any
significant bacteria or fungi, and serum levels of anti-td. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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Figure 1 The patient underwent radiation therapy for spinal bone metastasis. The spinal compression from the RCC bone metastasis (A).
The irradiated region is shown in the horizontal section (B) and the coronal section (C).
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and sialylated carbohydrate antigen KL-6 were within the
normal range. Although he was observed without suni-
tinib administration, the patient developed progressive
fever with worsening of dyspnea and general weakness
(Figure 2B). Treatment with pulse administration of
prednisolone 1,000 mg for 3 days was initiated along
with antifungal agent (voriconazole) and antibiotic
(meropenem hydrate) treatment. After the steroid pulseA
B
Figure 2 Radiation recall pneumonitis induced by sunitinib. On the 14
During follow-up without sunitinib, consolidation developed along with pr
that the interstitial filtration was localized in the previously irradiated area (
treatment was observed (D).therapy, the symptoms gradually improved over 7 days.
The radiological findings revealed that the interstitial
filtration was localized within the previously irradiated
area (Figure 2C). Therefore, the patient was diagnosed
with radiation recall pneumonitis that was induced by
sunitinib. During the treatment, serial sputum specimen
and blood culture examinations did not reveal any sig-
nificant bacteria or fungus. The patient recovered from
the interstitial lung disease completely during theC
D
th day of sunitinib induction, bilateral lung consolidation appeared (A).
ogressive fever (B). After steroid pulse therapy, the CT findings revealed
C). No evidence of relapse of recall pneumonitis during sorafenib
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going targeted therapy with another tyrosine kinase in-
hibitor, sorafenib, with no evidence of relapse of the
tyrosine kinase inhibitor-associated recall pneumonitis.
Discussion
The radiation recall phenomenon has been reported in
the skin, lung, and mucosa [5-7]. Causal agents have
been reported to be cytotoxic agents, including actino-
mycin D, gemcitabine, taxanes, and anthracyclines, and
the estrogen receptor antagonist tamoxifen [5-7]. In most
cases, dermatitis is reported. Radiation recall pneumonitis
appears to be relatively rare. The mechanism of the recall
response remains to be clarified. It has been proposed that
it is the result of the inhibition of cellular recovery by
cytotoxic agents after damage caused by radiation [6-8]. It
is possible that prevention of angiogenesis by sunitinib
reduces the recovery from the radiation-induced cell da-
mage. Alternatively, radiation injury may induce hypersen-
sitivity to sunitinib [6-8]. Alternatively, radiation injury
may induce hypersensitivity to sunitinib [6-8].
A case of interstitial pneumonitis during targeted therapy
with sunitinib is reported here. Pulmonary damage com-
monly occurs with doses more than 30 Gy and usually
develops 1–6 months after cessation of radiation therapy to
the lung. In the present case, the total dose of the radiation
that was administered to the patient was only 24 Gy. Since
the volume of lung that received more than 20 Gy (V20)
was only 2% (Figure 1C) and the patient had received ra-
diation therapy within one month before the onset of the
pneumonitis, it was considered to be unlikely to be
radiation-induced pneumonitis. Therefore, it was con-
cluded that the pneumonitis was recall pneumonitis
induced by sunitinib. There is currently only one report of
recall pneumonitis during sunitinib therapy [4]. In that re-
port, a female patient with RCC developed pneumonitis
more than 6 months after sunitinib induction and the com-
pletion of radiation therapy (30 Gy: 5 fraction) [4]. Her
pneumonitis resolved completely when the dose of suniti-
nib was reduced (from 50 mg/day to 37.5 mg/day); ste-
roids were not administered [4]. Thus, this case differs
from the present case in terms of the time of onset, the ra-
diation dose that was administered, and the severity of the
pneumonitis.
Although how sunitinib interacts with radiation therapy
remains unclear, this interaction may lead to synergistic
toxicities. There has been a report of lethal small bowel
perforation after radiation for lumbar metastasis during
sorafenib administration; moreover, the case of a lethal
bronchial fistula that occurred after radiation for mediasti-
num lymph node metastasis during sunitinib therapy was
published [9,10]. The current knowledge about the com-
bination of tyrosine kinase inhibitors with radiation the-
rapy has been reviewed by Niyazi et al. [7]. At present, itseems that none of the tyrosine kinase inhibitors have been
approved for simultaneous use with radiation therapy.
Conclusions
In conclusion, a case of early onset recall pneumonitis
during targeted therapy with sunitinib was reported
here. At present, how sunitinib interacts with radiation
therapy remains unclear. The possibility that tyrosine
kinase inhibitor therapy, including with sunitinib, after
radiation therapy may lead to adverse effects should be
kept in mind.
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